Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1626 1699 4121
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18250404 | METHODS FOR TREATING HEMATOLOGIC MALIGNANCIES WITH AMINO-PYRROLOPYRIMIDINONE COMPOUNDS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18137151 | RIFABUTIN FOR THE TREATMENT OF ACINETOBACTER BAUMANNII | Final Rejection | University of Southern California |
| 18041241 | QUORUM SENSING INHIBITORS AND METHODS OF USE | Final Rejection | The Trustees of Indiana University |
| 18312418 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | Final Rejection | Promega Corporation |
| 18041193 | PROTEASOME ENHANCERS AND USES THEREOF | Non-Final OA | Board of Trustees of Michigan State University |
| 18221140 | MITOCHONDRIA-TARGETING PEPTIDES | Non-Final OA | Stealth BioTherapeutics Inc. |
| 17908434 | IONTOPHORETIC COMPOSITION FOR ADMINISTERING S-KETAMINE | Final Rejection | LTS LOHMANN THERAPIE-SYSTEME AG |
| 17131312 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS | Final Rejection | Boehringer Ingelheim Vetmedica GmbH |
| 18565204 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | Non-Final OA | STINGINN INC. |
| 18549767 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | Non-Final OA | DiCE Molecules SV, Inc. |
| 18273878 | USE OF INDOLE, 6- AND 7-AZAINDOLE DERIVATIVES AS INHIBITORS OF FERROPTOSIS REGULATED CELL DEATH | Non-Final OA | Universite de Rennes 1 |
| 18268950 | METHODS FOR DELAY OF EJACULATION IN HUMAN MALES | Non-Final OA | Kanna Health Limited |
| 18265915 | EGANELISIB FOR USE IN THE TREATMENT OF PD-L1 NEGATIVE CANCER | Non-Final OA | Twelve Therapeutics, Inc |
| 18318192 | APPLICATION OF N1-DIHYDROCAFFEOYL-N10-CAFFEOYLSPERMIDINE IN PREPARATION OF DRUG, HEALTH PRODUCT OR FUNCTIONAL FOOD | Final Rejection | NINGXIA MEDICAL UNIVERSITY |
| 18246979 | Hexadeca Ammonium-Modified Phthalocyanine and Preparation Method and Use Thereof as Photodynamic Drug | Non-Final OA | Fuzhou University |
| 18192094 | USE OF NERIDRONIC ACID OR OF ITS SALT FOR THE TREATMENT OF OSTEOARTHROSIS | Final Rejection | ABIOGEN PHARMA S.P.A. |
| 18020966 | USE OF SORAFENIB IN TREATMENT OF TYPE 1 DIABETES | Non-Final OA | THE SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY |
| 18001427 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | Final Rejection | Arthrosi Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy